Loading...
XHKG
2348
Market cap191mUSD
Jul 10, Last price  
1.00HKD
1D
0.00%
1Q
-10.71%
Jan 2017
-57.08%
IPO
135.29%
Name

Dawnrays Pharmaceutical (Holdings) Ltd

Chart & Performance

D1W1MN
XHKG:2348 chart
P/E
6.08
P/S
1.06
EPS
0.14
Div Yield, %
6.30%
Shrs. gr., 5y
-0.55%
Rev. gr., 5y
3.74%
Revenues
1.23b
+16.09%
788,797,000919,945,000947,710,0001,082,110,0001,286,683,0001,081,044,000856,539,000914,973,000783,803,000985,000,000824,351,000882,483,000948,938,000950,007,0001,024,270,0001,165,155,0001,277,682,0001,151,145,0001,060,309,0001,230,867,000
Net income
214m
-62.13%
65,878,000101,157,000102,037,000118,388,000166,840,000146,307,000114,506,000153,099,000205,145,000302,198,000265,917,000292,978,000303,960,000255,430,000268,130,000358,175,000358,057,000326,000,000564,940,000213,971,000
CFO
355m
+61.40%
50,613,000130,551,00097,799,000138,987,000252,344,00082,986,000203,624,000231,262,000377,798,000298,322,000320,258,000390,741,000274,294,000275,837,000302,903,000393,139,000434,266,000338,400,000220,200,000355,406,000
Dividend
Sep 16, 20250.015 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Dawnrays Pharmaceutical (Holdings) Limited operates as an investment holding company, primarily engaged in the creation, production, and global distribution of generic pharmaceutical medicines, with a focus on Mainland China and international markets. Its operations are divided into two main divisions: Intermediates and Bulk Medicines, and Finished Drugs. The company's diverse product portfolio features a range of antibiotics, including pharmaceutical intermediates, bulk active ingredients, powdered formulations for injection, and oral antibiotic preparations. Furthermore, Dawnrays offers specialized medications addressing various bodily systems and conditions, such as those for cardiovascular health, allergies, Hepatitis B Virus (HBV), digestive and urinary issues, antipyretic-analgesic (fever and pain relief), respiratory ailments, and endocrine disorders. These system-specific drugs are dispensed in familiar forms like tablets, capsules, and granules. Founded in 1995, the firm maintains its headquarters in Wan Chai, Hong Kong, and is a subsidiary of Fortune United Group Limited.
IPO date
Jul 11, 2003
Employees
1,132
Domiciled in
HK
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT